Adaptimmune Therapeutics (ADAP) Tops Q2 EPS by 9c

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $128.2 million versus the consensus estimate of $40.47 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Eledon Pharamceuticals (ELDN) PT Raised to $7 at Leerink
• Lockheed Martin wins $83 million Army missile contract